Dr. Alexander Menter
Claim this profileKaiser Permanente-Franklin
About Alexander Menter
Education:
- Obtained a Medical Degree (MD) from the University of Colorado School of Medicine in 2015.
- Completed a Residency in Internal Medicine at the University of Colorado Hospital in 2018.
- Finished a Fellowship in Hematology/Oncology at the University of Colorado Anschutz Medical Campus in 2021.
Experience:
- Currently practices as a Hematologist/Oncologist at Kaiser Permanente Lone Tree Medical Offices.
Area of expertise
Lung Cancer
Alexander Menter has run 8 trials for Lung Cancer. Some of their research focus areas include:
Cancer
Alexander Menter has run 8 trials for Cancer. Some of their research focus areas include:
Affiliated Hospitals
Kaiser Permanente-Franklin
Kaiser Permanente-Rock Creek
Clinical Trials Alexander Menter is currently running
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting
2 awards
Phase 3
31 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting
2 awards
Phase 3
27 criteria
More about Alexander Menter
Clinical Trial Related
7 years of experience running clinical trials · Led 31 trials as a Principal Investigator · 7 Active Clinical Trials
Treatments Alexander Menter has experience with
- Pembrolizumab
- Nivolumab
- Ipilimumab
- Bevacizumab
- Biospecimen Collection
- Atezolizumab
Breakdown of trials Alexander Menter has run
Lung Cancer
Cancer
Non-Small Cell Lung Cancer
Colon Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Alexander Menter specialize in?
Alexander Menter focuses on Lung Cancer and Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage II.
Is Alexander Menter currently recruiting for clinical trials?
Yes, Alexander Menter is currently recruiting for 7 clinical trials in Denver Colorado. If you're interested in participating, you should apply.
Are there any treatments that Alexander Menter has studied deeply?
Yes, Alexander Menter has studied treatments such as Pembrolizumab, Nivolumab, Ipilimumab.
What is the best way to schedule an appointment with Alexander Menter?
Apply for one of the trials that Alexander Menter is conducting.
What is the office address of Alexander Menter?
The office of Alexander Menter is located at: Kaiser Permanente-Franklin, Denver, Colorado 80205 United States. This is the address for their practice at the Kaiser Permanente-Franklin.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.